ReviewFood science & nutrition2026
Food and Medicine Homologous Plants in Osteoporosis: A Scoping Review of Preclinical Evidence.
Review in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a chronic systemic bone disease characterized by reduced bone density and an increased risk of fractures. This review summarizes the preclinical evidence for 61 FMH plants and their active ingredients. Its bone protection mechanism involves estrogen-like action, inhibition of oxidative stress, regulation of intestinal flora and metabolites, regulation of autophagy, and other pathways. Based on a tertiary level of evidence, 24 plants had only a single animal/in vitro study (level 1), 34 had consistent results from multiple independent animal studies (level 2), and a few had preliminary human trials with obvious limitations (level 3). The existing evidence does not support FMH to replace standard anti-osteoporotic drugs and should be positioned as an adjunctive strategy for long-term prevention and early intervention, with standardized extracts and clinical trials with fractures as the endpoint in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.